Aneuploidy is frequently detected in human cancers and is implicated in carcinogenesis.
presence of activated KRAS mutations.
Introduction
Cyclin-dependent kinases (CDK) regulate cell cycle progression (1) . CDK2 is activated by the temporal upregulation of cyclin E promoting DNA duplication, entry and progression through the cell cycle (2) . Cyclin E-CDK2 deregulation is frequent in epithelial carcinogenesis, including in lung cancer where it is associated with a poor prognosis (3) .
Transgenic mouse models were engineered with surfactant C-targeted cyclin E expression in the lung (4) . This conferred chromosomal instability and lung cancers in mice with tumors recapitulating key features of human lung carcinogenesis (4).
Our prior work reported CDK2 inhibition caused anaphase catastrophe and apoptosis in lung cancer cells (5) . Results from a high-throughput screen system testing the effect of seliciclib in 270 cancer cell lines revealed that in non-small cell lung cancer (NSCLC) cell lines, the most sensitive lines frequently had activated KRAS, while the 15 least sensitive cell lines all had wild-type KRAS, indicating that KRAS mutant lung cancer cell lines are most sensitive to CDK2 inhibition (5) . Notably, lung cancer cases with activated KRAS are chemoresistant and have a poor prognosis (6) . Therapeutic strategies for lung cancers with KRAS mutations are needed. This study sought to elucidate mechanistic pathways through which CDK2 inhibition confers anaphase catastrophe, and how KRAS mutation enhances this effect.
Anaphase catastrophe is observed in cancers with extra centrosomes that segregate Research. on April 13, 2017. © 2015 American Association for Cancer cancerres.aacrjournals.org Downloaded from Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited.
Author Manuscript Published OnlineFirst on March 25, 2015 ; DOI: 10.1158/0008-5472. CAN-14-1494 chromosomes with multipolar spindles into non-viable cells (7, 8) . Centrosome amplification occurs in diverse cancers and is associated with chromosome instability, anaphase catastrophe, aneuploidy and tumorigenesis (9-13). Agents that cause anaphase catastrophe, including CDK2 inhibitors, exploit the fact that cancer cells with supernumerary centrosomes can undergo multipolar cell division, leading to aneuploidy and cell death (14) .
To identify potential mediators of anaphase catastrophe engaged by CDK2 inhibition, several CDK2 targets were examined. Among them, the centrosomal protein CP110 was highlighted since CP110 knockdown increased anaphase catastrophe in lung cancer cells.
CP110 is a direct target of cyclin E-CDK2, cyclin A-CDK2, and cyclin B-CDC2 (15) . CP110 has differing roles dependent on cell cycle phase (15) (16) (17) (18) (19) (20) . During the G1/S phase, CP110
regulates centrosome duplication and maturation (15, 16) and during the M phase it is involved in cytokinesis (17) . In non-cycling cells and cells in G0 phase, CP110 inhibits primary cilia formation (18, 19) . CP110 knockdown prevents centrosome reduplication in S-phase-arrested cells and induces premature centrosome separation (15) , resulting in tetraploidy and binucleate cells indicating cytokinesis failure (17) .
This study demonstrates in lung cancer cells that CDK2 inhibition causes multipolar anaphase that temporally precedes apoptosis and cell death. We found that CP110 is a mediator of CDK2-inhibitor-mediated anaphase catastrophe. Intriguingly, KRAS mutations sensitized lung cancers to CDK2-inhibitor-mediated anaphase catastrophe by deregulating database and by investigating lung cancers from engineered mouse models. Findings presented here reveal a direct role for CP110 in lung cancer response to CDK2 inhibition, especially when KRAS mutations were detected.
Materials and Methods

Chemicals and antibodies
Seliciclib (CYC202, R-roscovitine) was provided by Cyclacel (stock solution 10mM in dimethyl sulfoxide, DMSO). Dosages of seliciclib used in the study (5μM, 10μM and 15μM) are clinically achievable (21) and biological effects of seliciclib at those dosages were due to CDK2 inhibition rather than to CDK7/9 blockade (5). Antibodies used were: cytochrome C (556432, BD Pharmingen. 1:1000), α-tubulin (T6199, Sigma Aldrich. 1:10000), CP110 Pro-Long Gold anti-fade reagent with 4',6-diamidino-2-phenylindole (DAPI) (P36935, Invitrogen) preserved immunofluorescence.
Cell culture
The murine lung cancer cell line ED-1 was derived and cultured, as described (22 lung cancer cell lines Hop62, A549, H460 and H522 were purchased from ATCC and cultured as described (22) .
Live cell imaging
Cells plated on coverslips were treated with seliciclib (15M) or vehicle for 24 hours before live cell imaging. Multipolar metaphase cells were individually selected for time-lapse live cell imaging, as described (8). DIC images were acquired with a Nikon Eclipse Ti microscope and an Andor cooled CCD camera using a 60x1.4NA oil immersion objective.
For Hop62 cell imaging, 21 z-axis optical sections of 0.5 micron were acquired at 10 min intervals for 25 hours.
Following time-lapse imaging, cells were fixed with 3.5% paraformaldehyde and stained with DAPI and a cytochrome C-specific antibody. Fluorescent images were acquired using 11 z-axis optical sections of 1.0 micron. Image stacks and full volume renderings were performed using Nikon Elements and contrast enhancement was aided by Adobe Photoshop software. Cytochrome C immunofluorescence images were quantified by calculating average (mean) of the mean pixel intensity of at least 20 regions of interest (area= 0.8micron
2 ) within each cell to avoid any mitochondrial staining and quantify only cytoplasmic cytochrome C. Background levels for each image were subtracted.
Expression plasmids and transient transfection
HA-tagged wild-type pcDEF3-CP110 (CP110-WT) vector and a CP110 vector with 8 phosphorylation sites mutated pcDEF3-CP110 (CP110-MUT) were generous gifts from others (15 were each transiently transfected using TransIT-LT1 reagent (Mirus), following the manufacturer's instructions. Each experiment was independently replicated at least three times.
Indicated lung cancer cells were transfected with small interfering RNAs (siRNAs) using Lipofectamine 2000 (Invitrogen). The siRNAs targeting murine CP110 (Dharmacon), human or murine CDK2 (IDT) and human or murine KRAS (Thermo Scientific) species and RISC control siRNA (Dharmacon, IDT and Thermo Scientific) were purchased and validated for effects of each knock-down by immunblot and qPCR assays. SiRNA sequences appear in Supplementary File. S1. Each experiment was independently replicated at least three times.
Multipolar anaphase assay
Indicated lung cancer cells were fixed in cold methanol and stained with DAPI and an anti-α-tubulin-specific antibody and examined using an Eclipse TE 2000-E microscope (Nikon). Anaphase cells that contained three or more spindle poles were scored as multipolar. Data were expressed as percent multipolar versus total anaphase cells.
Generation of stable KRAS transfectants
Logarithmically growing ED-1 cells (3×10 6 ) were plated in each 10 cm tissue culture dish, 24 hours before transfection. Twelve μg each of the pCGN K-Ras G12V, 188L plasmid (Addgene) with the pPUR expression plasmid (Clontech) or an empty vector with the pPUR plasmid were individually transfected into ED-1 cells using Lipofectamine 2000 (Invitrogen).
Puromycin selection began 24 hours after transfection. Engineered KRAS overexpression was confirmed by immunoblot analysis.
Research. confirmed using a blocking peptide (sc-136629, Santa Cruz Biotechnology Inc.). The immunohistochemistry scoring system was similar to prior work (22, 25) . CP110 immunohistochemical expression was scored by a reference pathologist who was unaware of clinical findings. Both average staining intensity and percentages of immunoreactive cancer cells were recorded.
CP110 imunohistochemical analyses were independently performed in paired normal-malignant lung tissues from cyclin E as well as KRAS-driven lung cancers in engineered mouse models (4, 26) .
Immunoblot analyses
Cells were lysed with ice-cold radioimmunoprecipitation (RIPA) buffer with protease inhibitors (Biosciences), and immunoblot analyses performed as previously described (27) .
Lysates were size-fractionated by sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) before transfer to nitrocellulose membranes (Schleicher and Schuell Bioscience) and probing with indicated antibodies.
Real-time reverse transcription-PCR assays
Total RNA was isolated from cells using the RNA easy kit (Invitrogen). Reverse transcription (RT) was done using the High Capacity cDNA Reverse Transcription kit manufacturer's protocol (Applied Biosystems). Three replicate experiments were done.
Primers sequences appear in Supplementary File S1.
Statistical analyses
Results of independent experiments were pooled to assess statistical significance. Two-tailed t-tests were used. Statistical significance was noted with *, P < 0.05 and **, P < 0.01. cytoplasmic cytochrome C signal. However, the third daughter cell displayed marked DNA fragmentation and micronuclei, features seen before cell death or senescence (28) . These results provide direct evidence that progeny of lung cancer cells undergoing multipolar anaphases can undergo apoptosis.
Results
Live cell imaging after CDK2 inhibition
CP110 regulates anaphase catastrophe
Since CP110 regulates centrosome function and is a direct CDK2 phosphorylation target (15) , it was hypothesized CDK2 inhibition induced anaphase catastrophe via CP110. simultaneously overexpressed in ED-1 cells (Fig.2B) . CP110 overexpression was confirmed by immunoblot analyses (Supplementary Fig.S1A ) and CDK2 knockdown was validated by real-time quantitative RT-PCR assays and immunoblot analyses (Fig.2B, left panel) .
Overexpression of CP110 significantly antagonized multipolar anaphases induced by either Cdk2 knockdown (Fig.2B, middle panel) or seliciclib treatment (Fig.2B, right panel) . CP110 overexpression also significantly reduced apoptosis caused by seliciclib treatment (Supplementary Fig.S1B ).
To examine whether seliciclib treatment affected CP110 expression level, we examined basal levels of CP110 at 24 and 48 hours after seliciclib treatment. Treatment of seliclcib did not appreciably affect CP110 protein levels in human and murine lung cancer cells ( Supplementary Fig.S1E ).
To investigate whether CP110 phosphorylation was critical for protecting cells from 
The working model hypothesized that inhibition of CDK2 decreases CP110 phosphorylation levels, which leads to anaphase catastrophe. Moreover, activated KRAS can downregulate CP110 basal levels, increase lung cancer cellular response to CDK2 inhibitors (Schematic diagram in Supplementary Fig.S3A ).
Engineered CP110 overexpression in human lung cancer cells
To investigate whether CP110 overexpression can rescue anaphase catastrophe caused by CDK2 inhibition in human lung cancer cells, A549, Hop62, H460 and H522 cells were each engineered with CP110 overexpression (Supplementary Fig.S3B ) before seliciclib treatment (15μM) for 4, 8 and 24 hours. Induction of multipolar anaphases by CDK2 inhibition was observed as early as 4 hours after drug treatment of all four cell lines (Fig.3A) , while apoptosis induction did not occur until 24 hours of this treatment (Fig.3B) . 
To investigate the role of KRAS in seliciclib-mediated cytotoxicity, a KRAS G12V expression vector or an empty vector was independently stably transfected into ED-1 cells.
Expression of oncogenic KRAS was confirmed by immunoblot analyses (Fig.5A) . KRAS G12V transfected ED-1 cells (KRAS-ED-1) exhibited marked growth inhibition ( Supplementary   Fig.S4A ), increased multipolar anaphases (Fig.5A) and apoptosis (Fig.5B) after seliciclib treatment as compared to control transfectants. Thus, KRAS activation sensitized lung cancer cells to pharmacological CDK2 inhibition, as is consistent with previous work (5,7).
CP110 protein levels were down-regulated in KRAS-ED-1 cells, but CP110 mRNA levels were not appreciably affected as compared to control cells (Fig.5C ). CP110 protein levels were also lower in 344p, 393p and LKR13 murine lung cancer cells that harbor activating KRAS mutations as compared to ED-1 cells that express wild-type KRAS (Supplementary Fig.S4C ). To further explore the role of KRAS in regulating CP110 expression, transient KRAS knockdown was achieved in 344p and Hop62 cells using siRNAs. Decreased KRAS expression was detected at 48 and 72 hours after transfection. Fig.S4D and E) . This delay in a change in CP110 expression implied that CP110 expression was regulated by targets downstream of KRAS.
Increased CP110 expression was evident 72 hours after transfection for 344p cells and 96 hours after transfection for Hop62 cells (Supplementary
To learn whether CP110 overexpression could reverse KRAS-ED-1 cells sensitivity to CDK2 inhibition, wild-type CP110 was overexpressed in them. This reduced both multipolar anaphases and apoptosis ( Fig.5D and E) expression, which enhanced lung cancer cell response to CDK2 inhibition.
CP110 expression in lung cancers
To investigate whether CP110 was differentially expressed in human lung cancers with different KRAS mutation status, tumor histology, size, age or stage CP110 immunohistochemistry assays were performed (Fig.6A) .
In murine lung cancer cell lines driven by KRAS expression (LKR13) or not (ED-1), CP110 levels were 2.6 fold higher in ED-1 than in LKR13 cells (Supplementary Fig.S4C ).
Immunohistochemical expression profiles were also examined in the normal versus malignant lung tissues from KRAS or cyclin E-driven murine transgenic lung cancers ( Supplementary Fig.S5) . Notably, the intensity of CP110 staining was much lower in the KRAS-driven lung cancers as compared to lung cancers with wild-type KRAS status.
CP110 expression was higher in human malignant versus adjacent normal lung tissues ( Fig.6A and 6B) . A logistic regression model using CP110 intensity as a dichotomous outcome (CP110 intensity ≥ 200, median) revealed that a larger proportion of adenocarcinomas with KRAS mutations were low-CP110-intensity as compared with KRAS wild-type adenocarcinomas (Fig.6C) . However, average CP110 intensity did not show a difference between KRAS mutant and wild-type lung tumors (data not shown). No significant differences were observed in CP110 expression in lung cancer cases when stratified for survival (Fig.6D) , tumor stage or age at diagnosis (data not shown).
Discussion
This study revealed that CP110 expression determines the extent of anaphase should protect cancer cells with supernumerary centrosomes from undergoing multipolar cell division. High CP110 expression also inhibits primary cilia formation (18) . This contributes to cilia defects in cancer cells (32) . Primary cilia are crucial for signaling pathways through PDGFα, Hedgehog and Wnt, which are essential for growth and differentiation (34, 35) . Loss of cilia in cancer cells likely contributes to insensitivity of cancer cells to environmental repressive signals (34) . KRAS mutations can play a role in primary cilia formation in pancreatic cancers (36) . Of note, loss of primary cilia is important in cytogenesis in polycystic kidney disease and seliciclib treatment is reported to block cystogenesis in cultured cells and in mouse models of polycystic kidney disease, but ability to restore primary cilia formation was not examined (37) . The relationships between KRAS mutation, primary cilia formation, CDK2 inhibition, CP110 and lung carcinogenesis warrant further investigation.
The biological relevance of these findings was confirmed in lung cancers from engineered mice where KRAS is the driver mutation. These lung cancers exhibited lower CP110 levels as compared to lung cancers from mice with wild-type KRAS (Supplementary wild-type tumors when using logistic regression model categorizing tumors into high or low CP110 intensity (Fig.6C) . This finding supports the hypothesis that lung cancers with KRAS mutations are likely to be sensitive to a CDK2 inhibitor therapeutic strategy. One of the mechanisms underlying that is low CP110 levels increasing anaphase catastrophe.
Although the overall average CP110 levels between KRAS mutant and wild-type lung cancers did not show a significant difference, it is possible that the immunohistochemical assay used was not sufficiently sensitive to appreciate subtle differences in CP110 expression.
The effect of KRAS mutations on CP110 expression is likely complex and other proteins that interact with CP110 could be affected by KRAS mutations. For instance, CP110 expression is controlled by two independent ubiquitination pathways, SCF cyclinF -mediated pathway (20) and NEURL4-HERC2 complex-mediated pathway (38) . Recently, a centriolar deubiquitinating enzyme USP33 was found to regulate CP110 expression by countering cyclin-F-mediated destruction (25) .
In summary, this study identified CP110 as a key mediator of anaphase catastrophe induced by CDK2 inhibition that temporally precedes apoptosis. KRAS mutations sensitized lung cancer cells to seliciclib-mediated CDK2 inhibition, inducing anaphase catastrophe in part by down-regulating CP110 levels. The translational relevance of this finding is underscored by the fact that CP110 is frequently overexpressed in NSCLCs and a larger percentage of lung cancers with KRAS mutation are low-CP110-expressing. Taken together, these findings indicate a mechanistic link between CP110 expression and KRAS mutation. It
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